Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
Chemoresistance is a major therapeutic obstacle in the treatment of human pancreatic ductal adenocarcinoma (PDAC). As an oxidative stress responsive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the expression of cytoprotective genes. Nrf2 not only plays a critic...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-04-01
|
| Series: | Redox Biology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231718310073 |
| _version_ | 1818509832600158208 |
|---|---|
| author | Yunjiang Zhou Yang Zhou Mengdi Yang Keke Wang Yisi Liu Mingda Zhang Yunjia Yang Chenyu Jin Rui Wang Rong Hu |
| author_facet | Yunjiang Zhou Yang Zhou Mengdi Yang Keke Wang Yisi Liu Mingda Zhang Yunjia Yang Chenyu Jin Rui Wang Rong Hu |
| author_sort | Yunjiang Zhou |
| collection | DOAJ |
| description | Chemoresistance is a major therapeutic obstacle in the treatment of human pancreatic ductal adenocarcinoma (PDAC). As an oxidative stress responsive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the expression of cytoprotective genes. Nrf2 not only plays a critical role in chemoprevention, but also contributes to chemoresistance. In this study, we found that digoxin markedly reversed drug resistance of gemcitabine by inhibiting Nrf2 signaling in SW1990/Gem and Panc-1/Gem cells. Further research revealed that digoxin regulated Nrf2 at transcriptional level. In in vivo study, we found that digoxin and gemcitabine in combination inhibited tumor growth more substantially when compared with gemcitabine treatment alone in SW1990/Gem-shControl cells-derived xenografts. In the meantime, SW1990/Gem-shNrf2 cells-derived xenografts responded to gemcitabine and combination treatment similarly, suggesting that digoxin sensitized gemcitabine-resistant human pancreatic cancer to gemcitabine, which was Nrf2 dependent. These results demonstrated that digoxin might be used as a promising adjuvant sensitizer to reverse chemoresistance of gemcitabine-resistant pancreatic cancer to gemcitabine via inhibiting Nrf2 signaling. Keywords: Digoxin, Pancreatic cancer cells, Gemcitabine, Chemoresistance, Nrf2 |
| first_indexed | 2024-12-10T22:50:50Z |
| format | Article |
| id | doaj.art-d469bad7d94f4a29b0fcc7793f5a88b3 |
| institution | Directory Open Access Journal |
| issn | 2213-2317 |
| language | English |
| last_indexed | 2024-12-10T22:50:50Z |
| publishDate | 2019-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Redox Biology |
| spelling | doaj.art-d469bad7d94f4a29b0fcc7793f5a88b32022-12-22T01:30:26ZengElsevierRedox Biology2213-23172019-04-0122Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathwayYunjiang Zhou0Yang Zhou1Mengdi Yang2Keke Wang3Yisi Liu4Mingda Zhang5Yunjia Yang6Chenyu Jin7Rui Wang8Rong Hu9State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing 210009, ChinaCorrespondence to: Department of Physiology, China Pharmaceutical University, 24 Tongjia Xiang, Jiangsu, Nanjing 210009, China.; State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing 210009, ChinaChemoresistance is a major therapeutic obstacle in the treatment of human pancreatic ductal adenocarcinoma (PDAC). As an oxidative stress responsive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the expression of cytoprotective genes. Nrf2 not only plays a critical role in chemoprevention, but also contributes to chemoresistance. In this study, we found that digoxin markedly reversed drug resistance of gemcitabine by inhibiting Nrf2 signaling in SW1990/Gem and Panc-1/Gem cells. Further research revealed that digoxin regulated Nrf2 at transcriptional level. In in vivo study, we found that digoxin and gemcitabine in combination inhibited tumor growth more substantially when compared with gemcitabine treatment alone in SW1990/Gem-shControl cells-derived xenografts. In the meantime, SW1990/Gem-shNrf2 cells-derived xenografts responded to gemcitabine and combination treatment similarly, suggesting that digoxin sensitized gemcitabine-resistant human pancreatic cancer to gemcitabine, which was Nrf2 dependent. These results demonstrated that digoxin might be used as a promising adjuvant sensitizer to reverse chemoresistance of gemcitabine-resistant pancreatic cancer to gemcitabine via inhibiting Nrf2 signaling. Keywords: Digoxin, Pancreatic cancer cells, Gemcitabine, Chemoresistance, Nrf2http://www.sciencedirect.com/science/article/pii/S2213231718310073 |
| spellingShingle | Yunjiang Zhou Yang Zhou Mengdi Yang Keke Wang Yisi Liu Mingda Zhang Yunjia Yang Chenyu Jin Rui Wang Rong Hu Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway Redox Biology |
| title | Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway |
| title_full | Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway |
| title_fullStr | Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway |
| title_full_unstemmed | Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway |
| title_short | Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway |
| title_sort | digoxin sensitizes gemcitabine resistant pancreatic cancer cells to gemcitabine via inhibiting nrf2 signaling pathway |
| url | http://www.sciencedirect.com/science/article/pii/S2213231718310073 |
| work_keys_str_mv | AT yunjiangzhou digoxinsensitizesgemcitabineresistantpancreaticcancercellstogemcitabineviainhibitingnrf2signalingpathway AT yangzhou digoxinsensitizesgemcitabineresistantpancreaticcancercellstogemcitabineviainhibitingnrf2signalingpathway AT mengdiyang digoxinsensitizesgemcitabineresistantpancreaticcancercellstogemcitabineviainhibitingnrf2signalingpathway AT kekewang digoxinsensitizesgemcitabineresistantpancreaticcancercellstogemcitabineviainhibitingnrf2signalingpathway AT yisiliu digoxinsensitizesgemcitabineresistantpancreaticcancercellstogemcitabineviainhibitingnrf2signalingpathway AT mingdazhang digoxinsensitizesgemcitabineresistantpancreaticcancercellstogemcitabineviainhibitingnrf2signalingpathway AT yunjiayang digoxinsensitizesgemcitabineresistantpancreaticcancercellstogemcitabineviainhibitingnrf2signalingpathway AT chenyujin digoxinsensitizesgemcitabineresistantpancreaticcancercellstogemcitabineviainhibitingnrf2signalingpathway AT ruiwang digoxinsensitizesgemcitabineresistantpancreaticcancercellstogemcitabineviainhibitingnrf2signalingpathway AT ronghu digoxinsensitizesgemcitabineresistantpancreaticcancercellstogemcitabineviainhibitingnrf2signalingpathway |